Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 11/2020

01-11-2020 | SARS-CoV-2 | Notes From the Field

Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19

Authors: Adam W. Carrico, Keith J. Horvath, Christian Grov, Judith T. Moskowitz, Savita Pahwa, Suresh Pallikkuth, Sabina Hirshfield

Published in: AIDS and Behavior | Issue 11/2020

Login to get access

Excerpt

Among men who have sex with men (MSM), the co-occurrence of methamphetamine (meth) use and HIV could create a double jeopardy for coronavirus disease 2019 (COVID-19). Co-occurring meth and HIV could amplify biological and behavioral risk for infection with the novel coronavirus (SARS-CoV-2), presenting unique challenges to halting community-level transmission. This confluence of bio-behavioral risk factors related to meth and HIV may also synergistically enhance vulnerability to COVID-19 progression. Below we provide an overview of important areas for further research regarding the potential implications of the intertwining epidemics of meth use and HIV for the COVID-19 pandemic in MSM. …
Literature
1.
Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, et al. Amphetamine-group substances and HIV. Lancet. 2010;376(9739):458–74.CrossRef
2.
Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2(4):194–9.CrossRef
3.
Shoptaw S, Montgomery B, Williams CT, El-Bassel N, Aramrattana A, Metsch L, et al. Not just the needle: the state of HIV-prevention science among substance users and future directions. J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S174–S178178.CrossRef
4.
Carrico AW, Flentje A, Gruber VA, Woods WJ, Discepola MV, Dilworth SE, et al. Community-based harm reduction substance abuse treatment with methamphetamine-using men who have sex with men. J Urban Health. 2014;91(3):555–67.CrossRef
5.
Shoptaw S, Klausner JD, Reback CJ, Tierney S, Stansell J, Hare CB, et al. A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC Public Health. 2006;6:214.CrossRef
6.
Nanin JE, Parsons JT, Bimbi DS, Grov C, Brown JT. Community reactions to campaigns addressing crystal methamphetamine use among gay and bisexual men in New York City. J Drug Educ. 2006;36(4):297–315.CrossRef
7.
Robles F. Meth. The Forgotten killer, is back. And it’s everywhere. New York Times. 2018 02/14/2018.
8.
CDC. HIV infection risk, prevention, and testing behaviors among men who have sex with men—National HIV Behavioral Surveillance, 20 U.S. Cities, 2014. 2016.
9.
Hoenigl M, Chaillon A, Moore DJ, Morris SR, Smith DM, Little SJ. Clear links between starting methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. J Acquir Immune Defic Syndr. 2016;71(5):551–7.CrossRef
10.
11.
Mimiaga MJ, Reisner SL, Fontaine YM, Bland SE, Driscoll MA, Isenberg D, et al. Walking the line: stimulant use during sex and HIV risk behavior among Black urban MSM. Drug Alcohol Depend. 2010;110(1–2):30–7.CrossRef
12.
Carrico AW, Storholm ED, Flentje A, Arnold EA, Pollack LM, Neilands TB, et al. Spirituality/religiosity, substance use, and HIV testing among young black men who have sex with men. Drug Alcohol Depend. 2017;174:106–12.CrossRef
13.
Carrico AW, Zepf R, Meanley S, Batchelder A, Stall R. Critical review: when the party is over: a systematic review of behavioral interventions for substance-using men who have sex with men. J Acquir Immune Defic Syndr. 2016;73(3):299–306.CrossRef
14.
Vu NT, Maher L, Zablotska I. Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis. J Int AIDS Soc. 2015;18:19273.CrossRef
15.
Carrico AW, Hunt PW, Neilands TB, Dilworth SE, Martin JN, Deeks SG, et al. Stimulant use and viral suppression in the era of universal antiretroviral therapy. J Acquir Immune Defic Syndr. 2019;80:89–93.CrossRef
16.
Carrico AW, Riley ED, Johnson MO, Charlebois ED, Neilands TB, Remien RH, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56(2):146–50.CrossRef
17.
Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I, et al. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003;188(12):1820–6.CrossRef
18.
Horvath KJ, Carrico AW, Simoni J, Boyer EW, Amico KR, Petroll AE. Engagement in HIV medical care and technology use among stimulant-using and nonstimulant-using men who have sex with men. AIDS Res Treat. 2013;2013:121352.PubMedPubMedCentral
19.
Cook JA, Burke-Miller JK, Cohen MH, Cook RL, Vlahov D, Wilson TE, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008;22(11):1355–63.CrossRef
20.
Carrico AW, Shoptaw S, Cox C, Stall R, Li X, Ostrow DG, et al. Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(5):508–13.CrossRef
21.
Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51–83.CrossRef
22.
Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol. 2006;1(3):280–95.CrossRef
23.
Mata MM, Napier TC, Graves SM, Mahmood F, Raeisi S, Baum LL. Methamphetamine decreases CD4 T cell frequency and alters pro-inflammatory cytokine production in a model of drug abuse. Eur J Pharmacol. 2015;752:26–33.CrossRef
24.
Fulcher JA, Shoptaw S, Makgoeng SB, Elliott J, Ibarrondo FJ, Ragsdale A, et al. Brief report: recent methamphetamine use is associated with increased rectal mucosal inflammatory cytokines, regardless of HIV-1 serostatus. J Acquir Immune Defic Syndr. 2018;78(1):119–23.CrossRef
25.
Carrico AW, Flentje A, Kober K, Lee S, Hunt P, Riley ED, et al. Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. Brain Behav Immun. 2018;71:108–15.CrossRef
26.
Carrico AW, Cherenack EM, Roach ME, Riley ED, Oni O, Dilworth SE, et al. Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. AIDS. 2018;32(6):767–71.CrossRef
27.
Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228–38.
28.
Nou E, Lo J, Grinspoon SK. Inflammation, immune activation, and cardiovascular disease in HIV. AIDS. 2016;30(10):1495–509.CrossRef
29.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.CrossRef
30.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020;94(7):e0012720.CrossRef
31.
Henry BL, Minassian A, Perry W. Effect of methamphetamine dependence on heart rate variability. Addict Biol. 2012;17(3):648–58.CrossRef
32.
Persons AL, Bradaric BD, Dodiya HB, Ohene-Nyako M, Forsyth CB, Keshavarzian A, et al. Colon dysregulation in methamphetamine self-administering HIV-1 transgenic rats. PLoS ONE. 2018;13(1):e0190078.CrossRef
33.
Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2(32):32ra6.CrossRef
34.
35.
Elmousalami HH, Hassanien AB. Day level forecasting for Coronavirus Disease (COVID-19) spread: analysis, modeling and recommendations. arXiv preprint. 2020: arXiv:2003.07778
36.
37.
38.
Hoffman J. With meetings banned, millions struggle to stay sober on their own. New York Times. 2020.
39.
Moskowitz JT, Carrico AW, Duncan LG, Cohn MA, Cheung EO, Batchelder A, et al. Randomized controlled trial of a positive affect intervention for people newly diagnosed with HIV. J Consult Clin Psychol. 2017;85(5):409–23.CrossRef
40.
Carrico AW, Gomez W, Jain J, Shoptaw S, Discepola MV, Olem D, et al. Randomized controlled trial of a positive affect intervention for methamphetamine users. Drug Alcohol Depend. 2018;192:8–15.CrossRef
41.
Carrico AW, Neilands TB, Dilworth SE, Evans JL, Gomicronmez W, Jain JP, et al. Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine. J Int AIDS Soc. 2019;22(12):e25436.CrossRef
42.
Addington EL, Cheung EO, Bassett SM, Kwok I, Schuette SA, Shiu E, et al. The MARIGOLD study: feasibility and enhancement of an online intervention to improve emotion regulation in people with elevated depressive symptoms. J Affect Disord. 2019;257:352–64.CrossRef
43.
Bassett SM, Cohn M, Cotten P, Kwok I, Moskowitz JT. Feasibility and acceptability of an online positive affect intervention for those living with comorbid HIV depression. AIDS Behav. 2019;23(3):753–64.CrossRef
44.
Cheung EO, Cohn MA, Dunn LB, Melisko ME, Morgan S, Penedo FJ, et al. A randomized pilot trial of a positive affect skill intervention (lessons in linking affect and coping) for women with metastatic breast cancer. Psychooncology. 2017;26(12):2101–8.CrossRef
45.
Cohn MA, Pietrucha ME, Saslow LR, Hult JR, Moskowitz JT. An online positive affect skills intervention reduces depression in adults with type 2 diabetes. J Posit Psychol. 2014;9(6):523–34.CrossRef
46.
Reback CJ, Fletcher JB, Swendeman DA, Metzner M. Theory-based text-messaging to reduce methamphetamine use and HIV sexual risk behaviors among men who have sex with men: automated unidirectional delivery outperforms bidirectional peer interactive delivery. AIDS Behav. 2019;23(1):37–47.CrossRef
47.
Horvath KJ, Lammert S, MacLehose RF, Danh T, Baker JV, Carrico AW. A pilot study of a mobile app to support HIV antiretroviral therapy adherence among men who have sex with men who use stimulants. AIDS Behav. 2019;23(11):3184–98.CrossRef
Metadata
Title
Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19
Authors
Adam W. Carrico
Keith J. Horvath
Christian Grov
Judith T. Moskowitz
Savita Pahwa
Suresh Pallikkuth
Sabina Hirshfield
Publication date
01-11-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02854-w

Other articles of this Issue 11/2020

AIDS and Behavior 11/2020 Go to the issue

Original Paper

Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial

Original Paper

Personalized Cognitive Counseling Reduces Drinking Expectancy Among Men Who Have Sex with Men and Transgender Women in Lima, Peru: A Pilot Randomized Controlled Trial

Original Paper

HIV Prevalence and Factors Related to HIV Infection Among Transgender Women in Vietnam: A Respondent Driven Sampling Approach

Original Paper

Addressing Syndemics and Self-care in Individuals with Uncontrolled HIV: An Open Trial of a Transdiagnostic Treatment

Original Paper

Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with Men

Notes From The Field

Reimagining the Future of HIV Service Implementation in the Philippines Based on Lessons from COVID-19

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits